Adaptive Biotechnologies (ADPT) Tops Q3 EPS by 2c; Reports Cash and Cash Equivalents of $632.4M
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $28.61 +0.21%
Revenue Growth %: -23.8%
Financial Fact:
Operating loss: -32.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -23.8%
Financial Fact:
Operating loss: -32.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Adaptive Biotechnologies (NASDAQ: ADPT) reported Q3 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $39.5 million versus the consensus estimate of $36.64 million.
GUIDANCE:
Adaptive Biotechnologies sees FY2021 revenue of $148-155 million, versus the consensus of $152 million.
For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
